<DOC>
	<DOCNO>NCT00782041</DOCNO>
	<brief_summary>Primary : - To assess overall response rate oxaliplatin patient bidimensionally measurable disease baseline . Secondary : - To assess safety tolerability oxaliplatin - To assess time progression overall survival .</brief_summary>
	<brief_title>Patients Who Have Failed First Line Treatment Locally Advanced and/or Metastatic Cervical Cancer</brief_title>
	<detailed_description />
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Uterine Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Have Locally advanced/metastatic squamous adenocarcinoma cervix Prior therapy cisplatin allow Firstline treatment may surgery , radiotherapy chemotherapy either single agent multimodality therapy Must measurable disease Histologically Proven Carcinoma cervix ECOG PS ≤2 No serious concomitant illness Fully recover prior therapy Lab : ANC &gt; 1500 mm³ , Platelets &gt; 100000 mm³ , Creatinine ≤ 1.5 x Normal value , Bilirubin ≤ 1.5 x Normal value , SGPT ( ALT ) ≤ 2.5 x Normal value Known allergy one study drug Peripheral neuropathy &gt; grade2 The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>